1067 / 1816
EORTC IM-MS trial 22922/10925
1996-2004
Eligible: pN0 with centrally/medially tumour or pN+
R to +/- RT to IM-MS, mostly including IC3
50 Gy/25 fractions
Primary endpoint: OS
Secondary endpoints: DFS and BCM
4004 patients
Median follow up 10.9 yr